Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades912
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions2
HIK
Media
HIK Company
Research
HIK Company
Timeline2
Share Price Information for Hikma Pharmaceuticals (HIK)
Last checked at -
Last checked at 
Intraday Hikma Pharmaceuticals Share Chart
Friday broker round-up
Centrica: Berenberg reiterates hold with a target price of 45p.
NewRiver: Berenberg reiterates hold with a target price of 103p.
SSE: Berenberg reiterates hold with a target price of 1,300p.
Burford Capital: Canaccord reiterates sell with a target price of 570p.
Hikma Pharmaceuticals: Citigroup reiterates buy with a target price of 2,500p.
Morgan Advanced Materials: Citigroup reiterates buy with a target price of 275p.
RDI REIT: JP Morgan reiterates neutral with a target price of 75p.
DCC: JP Morgan reiterates overweight with a target price of 8,963p.
SSE: Deutsche Bank reiterates hold with a target price of 1,100p.
Ascential: Liberum reiterates buy with a target price of 420p.
Hammerson: Liberum reiterates hold with a target price of 250p.
Latest HIK News
- US Supreme Court backs generic drugmaker in 'skinny label' patent case
4 Jun 2026 - US Supreme Court backs generic drugmaker in 'skinny label' patent case
4 Jun 2026 - LONDON BROKER RATINGS: Citi cuts Severn Trent and United Utilities
5 May 2026 - UPDATE 1-US Supreme Court to hear 'skinny label' patent fight involving Amarin
29 Apr 2026 - Pfizer secures deals to keep heart drug free of generic rivals until 2031
28 Apr 2026 - UK dividends calendar - next 7 days
23 Apr 2026 - UK's Hikma Pharma backs outlook on faith in demand, managing Iran war costs
23 Apr 2026 - Hikma Pharmaceuticals backs outlook as Middle East demand stays robust
23 Apr 2026
Related News
WINNERS & LOSERS: Moonpig flying high as results beat consensus
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday.
IN BRIEF: Balfour Beatty wins GBP325 million Netherton Hub contract
Balfour Beatty PLC - London-based infrastructure construction - Secures a two-year contract worth GBP325 million from Scottish & Southern Electricity ...
Hikma Pharmaceuticals News
US Supreme Court backs generic drugmaker in 'skinny label' patent case
* Case involved Amarin's cardiovascular drug Vascepa
US Supreme Court backs generic drugmaker in 'skinny label' patent case
* Case involved Amarin's cardiovascular drug Vascepa
LONDON BROKER RATINGS: Citi cuts Severn Trent and United Utilities
(Alliance News) - The following London-listed shares received analyst recommendations on Tuesday morning and on Monday:
UPDATE 1-US Supreme Court to hear 'skinny label' patent fight involving Amarin
* Amarin Pharma sued British generic drug maker Hikma
Pfizer secures deals to keep heart drug free of generic rivals until 2031
April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster heart drug Vyndamax, ...
UK's Hikma Pharma backs outlook on faith in demand, managing Iran war costs
* Says Middle East demand robust, maintaining sufficient inventory
Hikma Pharmaceuticals backs outlook as Middle East demand stays robust
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated full year guidance following an "encouraging" start to the year, with all three bus...
Follow the stocks
